ArticleTranslational cancer research2024
HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions.
Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- SEI1 complex silences p53 to drive myeloma progression.iScience · 2026Article
- Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors.Signal transduction and targeted therapy · 2026Article
- [Potential Mechanisms and Research Advances of HDAC1 in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Review
- Electroacupuncture combined with HDAC1 inhibitor suppress tumor growth via improving the recruitment of intratumor CD8Frontiers in oncology · 2025Article
- Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many significant findings from recent studies have revealed the significance of histone deacetylase 1 (HDAC1) in the development of tumors and its strong association with tumor prognosis; these studies have mainly focused on one single cancer such as in lung cancer, breast cancer, and hepatocellular carcinoma (HCC). To date, there has been no comprehensive analysis and pan-analysis conducted from the overall perspective of cancer across all types. Hence, we analyzed public databases, conducted tube formation assay, and immunohistochemistry (IHC) staining of HDAC1 on six kinds of clinical samples to explore the prognostic and oncogenic effects of HDAC1 on 33 tumors for the first time. There currently remains a lack of efficient testing methods, therapies, and diagnostic and prognostic markers of tumor formation and development in different tumors. Methods: Our initial objective was to investigate the possible cancer-causing functions of HDAC1 in 33 different types of tumors by utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and many different online websites, such as Tumor IMmune Estimation Resource 2 (TIMER2), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Genotype Tissue Expression (GTEx) database, Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset, and University of ALabama at Brimingham CANcer data analysis portal (UALCAN) tool, and so on. We even used small interfering RNA (siRNA) to knock down HDAC2 in HCC cell lines. IHC of HDAC1 was performed. Results: HDAC1 exhibited high expression in numerous tumors, and strong correlations were observed between the messenger RNA (mRNA) levels of HDAC1 and the prognosis of individuals diagnosed with tumors. Human umbilical vein endothelial cells (HUVECs) tube formation and migration were significantly inhibited by conditioned media from HCC cells treated with siRNA of HDAC1. Several types of cancer have been found to exhibit elevated levels of phosphorylation at S421. Furthermore, as in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and kidney renal papillary cell carcinoma (KIRP), HDAC1 expression was found to be correlated with inflammatory cell infiltration. Conclusions: The levels of HDAC1 are expected to adapt to clinical adjuvant targeted therapy in most types of solid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.